Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

August 10, 2020 8:30 AM

IRVINE, CA / ACCESSWIRE / August 10, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that HJLI has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has evidenced full compliance with the stockholders' equity requirement for the continued listing of its shares on The Nasdaq Capital Market and, as a...

Read more

Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 10, 2020 7:00 AM

Company to Host an Investor Conference Call on Monday, August 10, 2020 at 8:00 AM EDT PRS-060/AZD1402 phase 2a trial in asthma to start in fourth quarter Signed clinical trial collaboration agreement with Lilly for supply of ramucirumab for phase 2 trial of PRS-343 PRS-343 phase 2 trial in gastric cancer to start this year PRS-343 phase 1 data to be presented in oral presentation session at ESMO Achievement of preclinical...

Read more

Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer

August 10, 2020 6:30 AM

BOSTON, MA / ACCESSWIRE / August 10, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the safety and efficacy of combining...

Read more

Tetra Bio-Pharma Virtually Opens the Market

August 7, 2020 10:30 AM

OTTAWA, ON / ACCESSWIRE / August 7, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that TBP common shares and warrants are now listed on the TSX (the "Common Shares") and (the "Warrants"). This occurred on August 4th, 2020. Dr. Guy Chamberland, CEO and Chief Regulatory Officer,...

Read more

Yulong Changes Name to EV Biologics

August 6, 2020 9:00 AM

CHEYENNE, WY / ACCESSWIRE / August 6, 2020 / Yulong Eco-Materials Limited (OTC PINK:YECO) today announced that it has changed its name to EV Biologics, Inc. The Company is in the process of filing the necessary forms with FINRA and CUSIP to change the name and get a new trading symbol. The Company moved its domicile from Cayman islands to Wyoming on April 12, 2019 and is currently in discussion to acquire a major USA based stem cell company...

Read more

CORRECTION FROM SOURCE: Tetra Bio-Pharma Provides Update on QIXLEEF(TM)'s European Activities

August 6, 2020 8:42 AM

Please disregard original release sent out and replace with the following. Tetra is accelerating its European activities Tetra's European project receives the approval and support from Malta Enterprise OTTAWA, ON / ACCESSWIRE / August 6, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the...

Read more

Apollo Endosurgery, Inc. Reports Second Quarter 2020 Results

August 4, 2020 4:01 PM

Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET AUSTIN, TX / ACCESSWIRE / August 4, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2020. Second Quarter 2020 and Recent Highlights As pre-announced, second quarter revenue was...

Read more

American CryoStem Issues Shareholder Update Letter

August 4, 2020 8:30 AM

EATONTOWN, NJ / ACCESSWIRE / August 4, 2020 / American CryoStem Corporation (OTC PINK:CRYO) (the "Company"), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, is pleased to issue the following shareholder update letter from Chief Executive Officer John Arnone. Dear American CryoStem family,...

Read more

Nascent Biotech & Manhattan BioSolutions Participate In a Panel Discussion On The TB Vaccine Development For COVID-19

August 4, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 4, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, has participated in the recent expert panel discussion entitled "BCG: a therapeutic modality for COVID-19 and cancers" hosted by the Bioidea Group (https://bioidea.co/2020/07/13/bcg-covid-19/). The virtual session featured...

Read more

Insurance Carrier Denial of Coverage for Calmare Pain Mitigation Therapy(TM) Overturned in California

August 3, 2020 12:45 PM

Independent Medical Review Organization Determined: "Denial Should Be Overturned" FAIRFIELD, CT / ACCESSWIRE / August 3, 2020 / Calmare Therapeutics Incorporated, (OTC PINK:CTTC), the pain mitigation company, announced today that the independent medical review organization ("IMRO"), in a rereview case filed with the California Department of Insurance, recommended overturning an insurance treatment coverage denial by the...

Read more

Pieris Pharmaceuticals to Host Second Quarter 2020 Investor Call and Corporate Update on August 10, 2020

August 3, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / August 3, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2020 investor call on Monday, August 10, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate...

Read more

Helix BioPharma Corp. to Present at the SNN Network Virtual Conference

July 31, 2020 5:05 PM

RICHMOND HILL, ON / ACCESSWIRE / July 31, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced it will be presenting at the SNN Network Virtual Conference on Monday, August 3rd at 2:30 PM EDT. Dr. Heman Chao, Helix's Chief Executive...

Read more

ABMC Reports First Quarter 2020 Results

July 31, 2020 4:00 PM

KINDERHOOK, NY / ACCESSWIRE / July 31, 2020 / American Bio Medica Corporation (OTC PINK:ABMC) today announced financial results for the three months ended March 31, 2020. Chief Executive Officer Melissa A. Waterhouse stated, "Our drug testing business has been negatively impacted by the Covid-19 pandemic. Here in the third quarter 2020, we are starting to see some improvement in drug test sales, however, as the pandemic continues, it is...

Read more

Apollo Endosurgery, Inc. to Report Second Quarter 2020 Results on August 4, 2020

July 30, 2020 4:05 PM

AUSTIN, TX / ACCESSWIRE / July 30, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the second quarter ended June 30, 2020 on Tuesday, August 4, 2020, after the U.S. stock markets close. Apollo will hold a conference call on Tuesday, August 4, 2020...

Read more

Dyadic to Report Second Quarter 2020 Financial Results on Thursday, August 13, 2020

July 30, 2020 4:00 PM

JUPITER, FL / ACCESSWIRE / July 30, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended June 30, 2020 after the...

Read more

Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments

July 30, 2020 8:05 AM

Jia Xie, PhD, a prominent researcher at Scripps Research responsible for inventing a collection of new technologies for antibody drug discovery and cell therapy Alexey V. Stepanov, PhD, a leading research expert in developing personalized therapeutic tools for lymphoproliferative disease using cell therapy Appointments bring valuable expertise to Scientific Advisory Board as the Company works to advance development of XCART through...

Read more

Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study

July 30, 2020 7:45 AM

TORONTO, ON / ACCESSWIRE / July 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. The company recently received expedited approval to begin the Phase 2/3 study...

Read more

Afecta Pharmaceuticals Announces Publication of Studies on Treatment of Malignant Melanoma

July 28, 2020 6:25 PM

IRVINE, CA / ACCESSWIRE / July 28, 2020 / Afecta Pharmaceuticals announces publication of a new study in collaboration with colleagues at the University of California at Irvine (UCI) that identifies novel mechanisms of action of Luteolin, a naturally occurring chemical found in several fruits and vegetables that inhibits growth of malignant melanoma in vitro and in vivo. The paper published in the journal Biochemical Pharmacology...

Read more

Binovi Provides Further Update to Its Filing of Annual and First Quarter Financial Statements

July 28, 2020 5:30 PM

TORONTO and  NEW YORK / ACCESSWIRE / July 28, 2020 /  Binovi Technologies Corp., (Binovi) (OTCQB:BNVIF)(TSXV:VISN ), a leader in neuro-vision performance technology announces that further to its news release dated June 29, 2020 the Company is continuing to rely on temporary blanket relief granted by Canadian securities regulators, allowing reporting issuers to extend certain continuous disclosure filing deadlines by 45 days....

Read more

Canam Biotech Inc. Applies for Temporary Exemption from Filing Its Quarterly Report for the Period Ended May 31, 2020 (Q2)

July 28, 2020 2:15 PM

VANCOUVER, BC / ACCESSWIRE / July 28, 2020 / Canam Biotech Inc. (formerly, HemaGenetics Technologies Corp.) (the "Company"), due to ongoing non-essential business shut down for COVID-19 measures taken by the Province of British Columbia, is relying on the exemption in BC Instrument 51-517 issued by the British Columbia Securities Commission and the reciprocating similar instrument issued by the Alberta Securities Commission allowing it...

Read more